 |
PDBsum entry 4lm1
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
4lm1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Identification and optimization of pde10a inhibitors using fragment-Based screening by nanocalorimetry and X-Ray crystallography.
|
 |
|
Authors
|
 |
M.I.Recht,
V.Sridhar,
J.Badger,
P.Y.Bounaud,
C.Logan,
B.Chie-Leon,
V.Nienaber,
F.E.Torres.
|
 |
|
Ref.
|
 |
J Biomol Screen, 2014,
19,
497-507.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Fragment-based lead discovery (FBLD) is a technique in which small,
low-complexity chemical fragments of 6 to 15 heavy atoms are screened for
binding to or inhibiting activity of the target. Hits are then linked and/or
elaborated into tightly binding ligands, ideally yielding early lead compounds
for drug discovery. Calorimetry provides a label-free method to assay binding
and enzymatic activity that is unaffected by the spectroscopic properties of the
sample. Conventional microcalorimetry is hampered by requiring large quantities
of reagents and long measurement times. Nanocalorimeters can overcome these
limitations of conventional isothermal titration calorimetry. Here we use
enthalpy arrays, which are arrays of nanocalorimeters, to perform an enzyme
activity-based fragment screen for competitive inhibitors of phosphodiesterase
10A (PDE10A). Two dozen fragments with KI <2 mM were identified and moved to
crystal soaking trials. All soak experiments yielded high-resolution
diffraction, with two-thirds of the fragments yielding high-resolution
co-crystal structures with PDE10A. The structural information was used to
elaborate fragment hits, yielding leads with KI <1 µM. This study shows how
array calorimetry can be used as a prescreening method for fragment-based lead
discovery with enzyme targets and paired successfully with an X-ray
crystallography secondary screen.
|
 |
|
|
|
|
 |